Elsevier, Clinical Lipidology (Third Edition): A Companion to Braunwald's Heart Disease, 2024, Pages 383-390.e2
Dyslipidemia and cardiovascular disease are substantial concerns for persons with HIV (PWH). Clinicians must be aware of the increased cardiovascular risk and screen PWH before initiation or after changes of HIV treatment. Personalized prevention and treatment plans should be initiated for PWH utilizing standard guidelines. Clinicians should also be aware of the drug–drug interactions with HIV treatments and cardiovascular risk interventions including antihypertensives and lipid-lowering agents.
